Stocks · News reference
BTIG analyst Marie Thibault reiterates Kestra Medical Techs (NASDAQ:KMTS) with a Buy and maintains $32 price target.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Phreesia reported Q3 2026 earnings of $0.03 per share, missing consensus estimates of $0.11 by 72.73%, though revenues slightly missed expectations at $129.46M. The stock has underperformed the S&P 500 by 41.5% year-to-date. With a Zacks Rank #3 (Hold) rating and mixed estimate revisions, the stock is expected to perform in line with the market near-term.
Kestra Medical Technologies announced the appointment of Curtis Kopf as Senior Vice President of Customer Experience in a newly created role. Kopf, who previously led global customer experience at Insulet Corporation and served as Chief Experience Officer at REI, will oversee the patient experience for the ASSURE WCD device. The appointment aligns with Kestra's investments in commercial capabilities and artificial intelligence initiatives to drive growth and improve patient support throughout their cardiac recovery journey.
Analysts changed ratings for GWRE, KMTS, CSQR, and STDN. See coverage details and price targets at Benzinga's analyst ratings page.